Glaukos Completes Patient Enrollment for GLK-321 Clinical Study
Glaukos announced completion of patient enrollment in its Phase 2 clinical study evaluating GLK-321 for the treatment of Demodex blepharitis. "Completion of enrollment in this Phase 2 study marks an important milestone in the advancement of our iLution pharmaceutical platform and broader ocular surface disease pipeline," said Thomas Burns, Glaukos chairman and chief executive officer. "Demodex blepharitis represents a large, growing, and significantly underpenetrated market opportunity, with potentially millions of patients who remain undiagnosed or untreated today. As awareness and diagnosis of this chronic condition continue to increase, we believe there is a substantial need for differentiated therapeutic approaches that expand treatment options and improve patient access to care."
